TechnoPhage

Since 2005, Technophage uses three different technologies to discover and create solutions for infection, neurosciences and ophthalmology. TechnoPhage’s strategy is based on developing new therapeutics from early discovery to clinical development. The company has its own GMP manufacturing plant specialized in the production of biologics, such as bacteriophages and small antibody fragments, and has recently concluded the first clinical trial of a Technophage proprietary product, which has also received a Fast Track Designation granted by the U.S. FDA. With three products currently in clinical phases, TechnoPhage is dedicated to expanding its portfolio of proprietary technologies and developing new products.